ResearcherUniversity of Colorado Cancer CenterActive in the last 2 years
Alexis Diane Leal
Matched on ORCID iD 0000-0002-0652-8151; OpenAlex author ID A5044333558. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 48
2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper
Papers 7
- Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
- Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Co-author DOI 10.1093/oncolo/oyae210↗
- Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL). Co-author DOI 10.1371/journal.pone.0298808↗
- Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. Co-author DOI 10.1158/2767-9764.crc-23-0065↗
- Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. Co-author DOI 10.1093/bjs/znab092↗
- Neoadjuvant treatment of localized pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo-20-250↗
- WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.642328↗
Closest collaborators
The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christopher Hanyoung Lieu · 5 shared papers, 2021–2024 · strength 0.76
- Paper Neoadjuvant treatment of localized pancreatic adenocarcinoma. DOI 10.21037/jgo-20-250↗
- Paper Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tum… DOI 10.1371/journal.pone.0298808↗
- Paper Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. DOI 10.1158/2767-9764.crc-23-0065↗
- Wells A. Messersmith · 5 shared papers, 2021–2024 · strength 0.76
- Paper Neoadjuvant treatment of localized pancreatic adenocarcinoma. DOI 10.21037/jgo-20-250↗
- Paper Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tum… DOI 10.1371/journal.pone.0298808↗
- Paper Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. DOI 10.1158/2767-9764.crc-23-0065↗
- Todd M. Pitts · 3 shared papers, 2021–2024 · strength 0.44
- Paper Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tum… DOI 10.1371/journal.pone.0298808↗
- Paper Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. DOI 10.1158/2767-9764.crc-23-0065↗
- Paper WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ducta… DOI 10.3389/fonc.2021.642328↗
- Zev A. Wainberg · 2 shared papers, 2024–2026 · strength 0.36
- Paper Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. DOI 10.1038/s41591-026-04734-7↗
- Paper Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the ope… DOI 10.1093/oncolo/oyae210↗
- Dana Backlund Cardin · 2 shared papers, 2024–2026 · strength 0.36
- Paper Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. DOI 10.1038/s41591-026-04734-7↗
- Paper Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the ope… DOI 10.1093/oncolo/oyae210↗
- Vincent M. Chung · 2 shared papers, 2024–2026 · strength 0.36
- Paper Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. DOI 10.1038/s41591-026-04734-7↗
- Paper Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the ope… DOI 10.1093/oncolo/oyae210↗
- Robert William Lentz · 2 shared papers, 2023–2024 · strength 0.33
- Paper Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tum… DOI 10.1371/journal.pone.0298808↗
- Paper Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. DOI 10.1158/2767-9764.crc-23-0065↗
- Sarah J. Hartman · 2 shared papers, 2021–2024 · strength 0.29
- Paper Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tum… DOI 10.1371/journal.pone.0298808↗
- Paper WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ducta… DOI 10.3389/fonc.2021.642328↗
- Sana D. Karam · 2 shared papers, 2021–2023 · strength 0.25
- Sarah Lindsey Davis · 2 shared papers, 2021 · strength 0.21
- Paper WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ducta… DOI 10.3389/fonc.2021.642328↗
- Paper Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. DOI 10.1093/bjs/znab092↗
- Harshabad Singh · 1 shared paper, 2026 · strength 0.19
- Jennifer Brooke Valerin · 1 shared paper, 2026 · strength 0.19
- Naomi H. Fei · 1 shared paper, 2026 · strength 0.19
- Andrew Eugene Hendifar · 1 shared paper, 2026 · strength 0.19
- Craig Devoe · 1 shared paper, 2026 · strength 0.19
- Syed Mohammad Ali Kazmi · 1 shared paper, 2026 · strength 0.19
- Jonathan D. Mizrahi · 1 shared paper, 2026 · strength 0.19
- Pashtoon Murtaza Kasi · 1 shared paper, 2026 · strength 0.19
- Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.19
- Ben George · 1 shared paper, 2026 · strength 0.19
- Peter J. Hosein · 1 shared paper, 2026 · strength 0.19
- Manuel M. Hidalgo · 1 shared paper, 2026 · strength 0.19
- Thomas J. George · 1 shared paper, 2026 · strength 0.19
- Tanios Bekaii‐Saab · 1 shared paper, 2026 · strength 0.19
- Mark H. O’Hara · 1 shared paper, 2026 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.